Form 8-K - Current report:
SEC Accession No. 0001558370-25-011297
Filing Date
2025-08-13
Accepted
2025-08-13 07:05:13
Documents
15
Period of Report
2025-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pmn-20250813x8k.htm   iXBRL 8-K 37700
2 EX-99.1 pmn-20250813xex99d1.htm EX-99.1 189274
3 GRAPHIC pmn-20250813xex99d1001.jpg GRAPHIC 6463
  Complete submission text file 0001558370-25-011297.txt   377793

Data Files

Seq Description Document Type Size
4 EX-101.SCH pmn-20250813.xsd EX-101.SCH 4155
5 EX-101.DEF pmn-20250813_def.xml EX-101.DEF 2871
6 EX-101.LAB pmn-20250813_lab.xml EX-101.LAB 17906
7 EX-101.PRE pmn-20250813_pre.xml EX-101.PRE 11837
17 EXTRACTED XBRL INSTANCE DOCUMENT pmn-20250813x8k_htm.xml XML 5044
Mailing Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2
Business Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2 416-847-6898
ProMIS Neurosciences Inc. (Filer) CIK: 0001374339 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)